Rare Disease Diagnostics Market (2026-2036)

The growth of this market is mainly driven by increasing awareness and early diagnosis initiatives, growing government support and funding for rare disease research and diagnosis, advancements in genomic technologies, the rising recognition of rare genetic disorders, and the increasing adoption of next-generation sequencing in clinical settings. In addition, the expansion of newborn screening into genomic sequencing, the growing number of genotype-directed therapies that require a confirmed molecular diagnosis, and widening reimbursement for exome and genome testing are further supporting the growth of this market.

The global Rare Disease Diagnostics Market is projected to reach USD 9.5 billion by 2036, driven by early diagnosis initiatives, growing government support for rare disease research and diagnosis, advancements in genomic technologies, and the increasing adoption of next-generation sequencing in clinical settings.

North America is expected to account for the largest market share of 45.2% in 2026, while Asia-Pacific is projected to register the fastest growth at a CAGR of 22.6% during the forecast period. China has catalogued 207 rare diseases, Japan has designated more than 330 intractable diseases, and South Korea supports genome sequencing for more than 1,300 eligible diseases.

By test type, Genetic Testing is expected to account for the largest market share of 82.3% in 2026 and to register the highest CAGR of 18.2% through 2036. Within next-generation sequencing, Whole Genome Sequencing (WGS) is projected to register the highest CAGR of 27.4%.

By disease type, Neurological Disorders are expected to dominate the market with a share of 33.1% in 2026 and to register the highest CAGR of 19.6% during the forecast period.

The cost of sequencing a human genome has fallen from approximately USD 100 million in 2001 to under USD 1,000, and exome and genome sequencing achieve diagnostic yields of 25% to 50% in selected patients, against 15% to 20% for chromosomal microarray in patients with developmental disabilities.

Test volume is growing faster than test value. GeneDx increased exome and genome volume by 34% in the first quarter of 2026 while revenue grew 17%, as expanded Medicaid coverage brought lower reimbursement rates, shifting value toward interpretation, curated genomic data, and reimbursement access.

The integration of genomic sequencing into newborn screening is expected to create significant long-term growth opportunities. Genomics England is sequencing the genomes of 100,000 newborns through the Generation Study, and U.S. programs screen each of 3.63 million annual births for 30 to more than 50 conditions using dried blood spots.

The Rare Disease Diagnostics Market comprises the genetic, biochemical, imaging, and other diagnostic tests used to identify rare diseases and to select patients for genotype-directed therapies. Rare diseases are conditions that affect fewer than 200,000 people in the U.S. or fewer than 1 in 2,000 people in Europe. More than 7,000 rare diseases have been identified, collectively affecting an estimated 300 to 400 million people worldwide, including approximately 25 to 30 million people in the U.S. and an estimated 30 million in the European Union, and approximately 80% have a genetic origin. The market includes next-generation sequencing (targeted gene panels, whole exome sequencing, and whole genome sequencing), chromosomal microarray, Sanger sequencing, karyotyping, fluorescence in situ hybridization (FISH), PCR-based testing, enzyme assays, metabolite analysis, and protein analysis, performed on blood, tissue, urine, saliva, amniotic fluid, and other sample types. The market ecosystem extends from raw material and component suppliers to diagnostic instrument and reagent manufacturers, reference and clinical testing laboratories, hospital laboratories, and the healthcare providers that order and act on test results.

The market is experiencing strong growth as genomic testing moves from specialized research programs into routine clinical care. The cost of sequencing a human genome has fallen from approximately USD 100 million in 2001 to under USD 1,000, which has made comprehensive genomic testing viable in place of sequential single-gene testing. Exome and genome sequencing achieve diagnostic yields of 25% to 50% in selected populations, including children with unexplained developmental delay and patients with multiple congenital anomalies. GeneDx grew exome and genome result volume by 30.5% in 2025 to 97,271 results, and Tempus, following its acquisition of Ambry Genetics, delivered approximately 801,000 tests in 2025, of which approximately 460,500 were hereditary tests.

Regulatory policy is also supporting market growth. The U.S. Food and Drug Administration (FDA) announced the Rare Disease Evidence Principles in September 2025 for therapies addressing diseases that affect fewer than 1,000 patients in the U.S. and are driven by a known genetic defect, and issued draft guidance on a Plausible Mechanism Framework for individualized genetic therapies on 23 February 2026. Each such therapy depends on a confirmed genetic diagnosis to identify the patient who can receive it, which links therapeutic development directly to diagnostic demand. In Europe, the European Rare Diseases Research Alliance began in September 2024 with an estimated budget of EUR 380 million for 2024 to 2031, while the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 has applied since May 2022, with legacy transition periods extended to 2027 to 2029.

Reimbursement is widening, although it remains uneven. Medicaid coverage for exome testing was extended in Texas, Maine, and Arkansas to approximately 4.9 million additional lives, and the Centers for Medicare and Medicaid Services set a reimbursement rate of USD 2,989.55 per test for the Illumina TruSight Oncology Comprehensive assay from 1 January 2026. Exome and genome tests typically cost USD 3,000 to USD 7,000 including sample processing, sequencing, bioinformatics, clinical interpretation, and reporting, against more than USD 20,000 when the tests were first introduced.

At the same time, newborn screening is expanding from biochemical assays into genomic sequencing. Newborn screening programs have relied on biochemical assays since the 1960s, at a cost per infant of approximately USD 100 to USD 200 for a comprehensive panel. The U.S. recorded 3,628,934 births in 2024, and state programs screen each infant for 30 to more than 50 conditions using dried blood spots. Genomics England is sequencing the genomes of 100,000 newborns through the Generation Study, and Australia is expanding newborn screening with AUD 68.3 million of Commonwealth funding. These programs are extending screening to conditions that biochemical assays cannot detect and are creating new, population-scale demand for sequencing and interpretation.

Rising awareness of rare diseases among patients, clinicians, and policymakers is a major factor driving the Rare Disease Diagnostics Market. Rare diseases collectively affect an estimated 300 to 400 million people worldwide, and Rare Disease Day, first held in 2008, is now marked in more than 100 countries, where patient organizations press for earlier referral and testing. Studies document that rare disease patients see an average of five to eight physicians over four to seven years before receiving an accurate diagnosis. Early diagnosis initiatives, including rapid genome sequencing for critically ill infants, which delivers results within days, and newborn screening programs that reach almost every infant in countries with established programs, are shortening this diagnostic odyssey and increasing demand for rare disease diagnostic tests.

Governments are strengthening policy and funding frameworks for rare disease research and diagnosis. In the U.S., the Orphan Drug Act of 1983 established incentives for rare disease therapeutic development, and the FDA announced the Rare Disease Evidence Principles in September 2025, under which approval can rest on one adequate and well-controlled study supported by confirmatory evidence. In Canada, the National Strategy for Drugs for Rare Diseases commits up to CAD 1.5 billion, including funding for screening and diagnosis. The European Rare Diseases Research Alliance began in September 2024 with an estimated budget of EUR 380 million, while national genomic medicine programs, including the NHS Genomic Medicine Service in England, the Plan France Médecine Génomique 2025, and the German genome sequencing model project, are integrating genome sequencing into routine care.

Advancements in genomic technologies are enabling better identification of rare diseases. The cost of sequencing a human genome has fallen to under USD 1,000, and Illumina reported an installed base of 890 NovaSeq X instruments at the end of 2025. Exome and genome sequencing achieve diagnostic yields of 25% to 50% in selected populations, and standard exome results are delivered within two to three weeks. Next-generation sequencing has moved from reference laboratories into routine clinical pathways: GeneDx grew exome and genome result volume by 32% in the second quarter of 2026 to 30,785 results. Each newly described gene-disease relationship adds a condition that genomic testing can detect, further expanding the addressable market.

Exome and genome tests typically cost USD 3,000 to USD 7,000 including sample processing, sequencing, bioinformatics, clinical interpretation, and reporting. Patients without insurance coverage or with high-deductible plans face substantial out-of-pocket costs, and repeat testing after a non-diagnostic result adds further cost. These costs limit accessibility, particularly in developing regions where public reimbursement for genomic testing is limited.

Primary care physicians in many developing regions receive limited training in medical genetics, and access to clinical geneticists and genetic counselors is concentrated in large urban hospitals. Patients presenting with non-specific symptoms are often treated for more common conditions before a genetic cause is considered, which lengthens the time to referral and delays testing.

In the European Union, the In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 requires clinical evidence, notified body review for most devices, and post-market performance follow-up. Regulation (EU) 2024/1860 extended the transition periods for legacy devices to 31 December 2027 for class D devices, 31 December 2028 for class C, and 31 December 2029 for class B and sterile class A devices, reflecting limited notified body capacity. Manufacturers of low-volume rare disease assays face the same evidence requirements as high-volume products, which raises the cost of compliance per test.

Newborn screening reaches almost every infant in countries with established programs, and genomic sequencing is extending screening to conditions that biochemical assays cannot detect. The UK heel-prick program screened ten conditions by late 2025, after tyrosinemia type 1 was added in October 2025, while coverage elsewhere in Europe ranges from 14 conditions in France and 27 in the Netherlands to more than 49 in Italy. Brazilian Law 14.154 of 2021 expands the public newborn screening program in Brazil to about 50 conditions. Population-scale genomic newborn screening research, including the Generation Study in England, is expected to create significant long-term demand for sequencing and interpretation.

Genotype-defined therapies require a molecular diagnosis to select patients. The FDA Plausible Mechanism Framework, issued in draft in February 2026, sets out how therapies for individual patients or very small groups can meet approval standards, citing the base-editing treatment of an infant with carbamoyl-phosphate synthetase 1 deficiency. As the number of approved and investigational genetic therapies grows, the diagnostic test becomes the entry point to treatment.

Pharmaceutical companies developing rare disease therapies need patients identified before they can enroll trials or launch products. Diagnostic companies supply sponsored testing, which is free to the patient and paid for by the drug developer, together with genomic datasets used to identify trial candidates and to understand disease progression. These collaborations provide diagnostic companies with additional revenue streams and help expand testing access.

Asia-Pacific is projected to record the highest CAGR of any region. China has a population of more than 1.4 billion and a developing genetic testing infrastructure, and the rare disease testing market in India is expanding as test prices fall. Strand Life Sciences, controlled by Reliance Industries, is positioned to offer genomic tests below INR 1,000, against approximately INR 10,000 for basic tests at present. In the Gulf, Saudi Arabia has sequenced more than 65,000 samples through its national program and the UAE has sequenced about 700,000 citizens.

Rare disease patients see an average of five to eight physicians over four to seven years before receiving an accurate diagnosis. Non-specific presentation, overlapping symptoms, and limited specialist access extend the process, and a large share of patients who undergo exome sequencing still receive no diagnosis, which requires reanalysis, broader testing, and functional studies.

Reimbursement for exome and genome sequencing varies by payer, indication, and region, and coverage often requires prior authorization and documented clinical criteria. Although coverage is widening, test volume is growing faster than test value, as newly covered Medicaid programs pay lower rates than commercial insurers, which puts pressure on laboratory revenue per test.

Newborn screening programs have relied on biochemical assays since the 1960s, at a cost per infant of approximately USD 100 to USD 200 for a comprehensive panel. Genomic sequencing extends screening to conditions that biochemical assays cannot detect, and research programs are now producing outcome data at population scale, including the sequencing of 100,000 newborn genomes through the Generation Study in England and multi-state genomic newborn screening initiatives in the U.S.

Artificial intelligence is applied to variant prioritization, phenotype matching, and facial analysis. Facial analysis tools such as Face2Gene have been trained on images spanning hundreds of genetic syndromes and are used by clinicians to shortlist candidate diagnoses, while variant interpretation systems rank the thousands of variants found in each exome by their likelihood of causing the presentation of the patient. As sequencing becomes a commodity input, value is moving toward interpretation, curated genomic data, and reimbursement access.

Based on test type, the global Rare Disease Diagnostics Market is segmented into Genetic Testing, Biochemical Testing, Imaging Diagnostics, and Other Diagnostic Tests. Genetic Testing is further segmented into Next-Generation Sequencing (NGS), Chromosomal Microarray (CMA), Sanger Sequencing, Karyotyping, Fluorescence In Situ Hybridization (FISH), and PCR-Based Testing, and Next-Generation Sequencing is further segmented into Targeted Gene Panels, Whole Exome Sequencing (WES), and Whole Genome Sequencing (WGS).

In 2026, the Genetic Testing segment is expected to account for the largest share of 82.3% of the global Rare Disease Diagnostics Market. The large share of this segment is mainly due to the genetic origin of approximately 80% of rare diseases and to the replacement of sequential single-gene testing with exome and genome sequencing, which achieve diagnostic yields of 25% to 50% in selected patients. This segment is also projected to register the highest CAGR of 18.2% during the forecast period. Within next-generation sequencing, Targeted Gene Panels are expected to account for the largest share in 2026, while Whole Genome Sequencing is projected to register the highest CAGR of 27.4%, driven by first-tier use in intensive care and by the move from exome to genome testing.

Based on disease type, the market is segmented into Neurological Disorders, Metabolic Disorders, Immunological Disorders, Hematological Disorders, Endocrine Disorders, Cardiovascular Rare Disorders, and Other Rare Diseases. In 2026, the Neurological Disorders segment is expected to account for the largest share of 33.1% of the rare disease diagnostics market due to the high genetic contribution to epilepsies, neurodevelopmental disorders, and neuromuscular diseases, and to evidence of economic benefit, including savings of up to USD 80,000 per child with a neurodevelopmental disorder in the 12 months after exome or genome testing. This segment is also projected to register the highest CAGR of 19.6% during the forecast period.

Based on technology, the market is segmented into Sequencing Technologies, PCR-Based Technologies, Mass Spectrometry, Microarray Technologies, Immunoassays, and Other Technologies. In 2026, Sequencing Technologies are expected to account for the largest share of 60.8% of the rare disease diagnostics market, because of the fall in genome sequencing cost to under USD 1,000 and the installed base of 890 NovaSeq X instruments reported by Illumina at the end of 2025. This segment is also projected to register the highest CAGR of 20.0% during the forecast period. Within PCR-based technologies, Digital PCR (dPCR) is projected to register the highest CAGR of 21.1%.

Based on sample type, the market is segmented into Blood Samples, Tissue Samples, Urine Samples, Saliva Samples, Amniotic Fluid, and Other Sample Types. In 2026, the Blood Samples segment is expected to account for the largest share of 72.8% of the rare disease diagnostics market due to the use of blood as the standard sample for germline sequencing and of dried blood spots in newborn screening. This segment is also projected to register the highest CAGR of 18.0% during the forecast period, while Saliva Samples are projected to register a CAGR of 17.2%, the highest among other sample types.

Based on end user, the market is segmented into Diagnostic Laboratories (Reference Laboratories and Clinical Laboratories), Hospital Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Other End Users. In 2026, the Diagnostic Laboratories segment is expected to account for the largest share of 52.3% of the rare disease diagnostics market due to the concentration of exome and genome testing in specialized reference laboratories with interpretation capability, and to consolidation that has increased their scale, including the acquisitions of Invitae assets by Labcorp and Ambry Genetics by Tempus. This segment is also projected to register the highest CAGR of 18.6% during the forecast period.

The global Rare Disease Diagnostics Market combines instrument and reagent manufacturers with testing laboratories that provide clinical interpretation. Market participants compete primarily on diagnostic yield, turnaround time, depth of curated genomic data, interpretation capability, reimbursement access, test menu breadth, and pricing.

Consolidation reshaped the laboratory tier between 2024 and 2026. Labcorp completed the acquisition of the Invitae genetic testing assets in August 2024, Tempus completed its USD 600 million acquisition of Ambry Genetics in 2025, and Eurofins acquired the clinical diagnostics operations of Synlab in Spain in March 2025. Among manufacturers, Illumina completed the acquisition of SomaLogic for USD 350 million in January 2026, QIAGEN acquired Parse Biosciences in December 2025, and Agilent completed the acquisition of Biocare Medical in June 2026. Acquisitions and investments, product launches, partnerships with health systems and pharmaceutical companies, and expansion of sequencing and interpretation capacity remain the key strategies adopted by leading companies.

The report provides a comprehensive competitive assessment of the leading companies operating in the global Rare Disease Diagnostics Market. The key players profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Revvity, Inc. (U.S.), Labcorp Holdings Inc. (U.S.), GeneDx Holdings Corp. (U.S.), Tempus AI, Inc. (U.S.), Fulgent Genetics, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Centogene GmbH (Germany), Blueprint Genetics (Finland), and Strand Life Sciences Pvt. Ltd. (India).